ISTA Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Irvine CA United States (1992)
Status: Acquired by Bausch & Lomb (2012) → now Bausch Health Companies (2013)

Organization Overview

First Clinical Trial
1998
NCT00198510
First Marketed Drug
2004
hyaluronidase (ovine) (Vitrase)
First NDA Approval
2004
hyaluronidase (ovine) (Vitrase)
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ISTA Pharmaceuticals, Inc.

Active Ingredients

Marketed Drugs (3)

bepotastine (bepreve) (2009 NDA)

bromfenac (xibrom) (2005 NDA)

hyaluronidase (ovine) (Vitrase) (2004 NDA)

Drugs in Phase 4 Trials (1)

hyaluronidase (ovine) (Vitrase) (7 trials)

Drugs in Phase 3 Trials (5)

bepotastine (bepreve) (7 trials)

bromfenac (xibrom) (7 trials)

ecabet (3 trials)

prednisone (meticorten) (3 trials)

tobramycin (nebcin) (3 trials)

Drugs in Phase 2 Trials (2)

cellulose (1 trial)

fluticasone (cutivate) (1 trial)

Drugs in Other Trials (1)

polyethylene glycol (1 trial)

Indications

Approved Indications


 

Conjunctivitis, Allergic

Inflammation

Pain

Rhinitis, Allergic

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 3)

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Diabetic Retinopathy (Phase 3)

Dissociative Disorders (Phase 2)

Drug Hypersensitivity (Phase 1)

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 2)

Eye Infections (Phase 3)

Hemorrhage (Phase 3)

Hypersensitivity (Phase 1)

Inflammation (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Postoperative Complications (Phase 3)

Retinal Diseases (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Syndrome (Phase 3)

Vitreous Detachment (Phase 2)

Vitreous Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 29
  • # of Trial APIs: 9